Abbott Laboratories (NYSE:ABT) Shares Sold by American Institute for Advanced Investment Management LLP

American Institute for Advanced Investment Management LLP lessened its holdings in shares of Abbott Laboratories (NYSE:ABTFree Report) by 2.4% in the fourth quarter, according to its most recent filing with the SEC. The firm owned 3,917 shares of the healthcare product maker’s stock after selling 97 shares during the quarter. American Institute for Advanced Investment Management LLP’s holdings in Abbott Laboratories were worth $431,000 as of its most recent SEC filing.

Other institutional investors also recently added to or reduced their stakes in the company. Halpern Financial Inc. acquired a new stake in shares of Abbott Laboratories during the third quarter worth $26,000. Altshuler Shaham Ltd acquired a new stake in shares of Abbott Laboratories during the fourth quarter worth $28,000. Cornerstone Planning Group LLC acquired a new stake in shares of Abbott Laboratories during the second quarter worth $28,000. CGC Financial Services LLC acquired a new stake in shares of Abbott Laboratories during the second quarter worth $32,000. Finally, FWL Investment Management LLC acquired a new position in Abbott Laboratories during the fourth quarter valued at $33,000. Institutional investors and hedge funds own 75.18% of the company’s stock.

Abbott Laboratories Trading Down 0.6 %

Abbott Laboratories stock opened at $111.31 on Thursday. The business has a 50 day moving average price of $115.03 and a two-hundred day moving average price of $106.77. The company has a quick ratio of 1.16, a current ratio of 1.64 and a debt-to-equity ratio of 0.35. The stock has a market cap of $193.14 billion, a price-to-earnings ratio of 34.14, a price-to-earnings-growth ratio of 2.70 and a beta of 0.74. Abbott Laboratories has a 12 month low of $89.67 and a 12 month high of $121.64.

Abbott Laboratories (NYSE:ABTGet Free Report) last posted its quarterly earnings results on Wednesday, January 24th. The healthcare product maker reported $1.19 EPS for the quarter, meeting the consensus estimate of $1.19. Abbott Laboratories had a return on equity of 20.65% and a net margin of 14.27%. The firm had revenue of $10.24 billion during the quarter, compared to analysts’ expectations of $10.19 billion. During the same quarter in the prior year, the firm posted $1.03 EPS. The company’s revenue for the quarter was up 1.5% on a year-over-year basis. As a group, equities analysts forecast that Abbott Laboratories will post 4.62 EPS for the current year.

Abbott Laboratories Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Wednesday, May 15th. Investors of record on Monday, April 15th will be paid a $0.55 dividend. This represents a $2.20 annualized dividend and a dividend yield of 1.98%. The ex-dividend date is Friday, April 12th. Abbott Laboratories’s dividend payout ratio (DPR) is currently 67.48%.

Insider Buying and Selling at Abbott Laboratories

In other Abbott Laboratories news, EVP Andrea F. Wainer sold 12,500 shares of the business’s stock in a transaction that occurred on Friday, February 23rd. The shares were sold at an average price of $120.00, for a total transaction of $1,500,000.00. Following the completion of the transaction, the executive vice president now directly owns 78,704 shares in the company, valued at $9,444,480. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. In other news, EVP Andrea F. Wainer sold 42,500 shares of the company’s stock in a transaction on Monday, January 29th. The shares were sold at an average price of $112.50, for a total transaction of $4,781,250.00. Following the completion of the transaction, the executive vice president now directly owns 65,027 shares in the company, valued at $7,315,537.50. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, EVP Andrea F. Wainer sold 12,500 shares of the company’s stock in a transaction on Friday, February 23rd. The stock was sold at an average price of $120.00, for a total transaction of $1,500,000.00. Following the transaction, the executive vice president now owns 78,704 shares of the company’s stock, valued at $9,444,480. The disclosure for this sale can be found here. Insiders sold a total of 56,435 shares of company stock worth $6,451,298 over the last three months. Corporate insiders own 0.47% of the company’s stock.

Analyst Upgrades and Downgrades

A number of brokerages have commented on ABT. Citigroup boosted their target price on Abbott Laboratories from $126.00 to $128.00 and gave the company a “buy” rating in a research note on Wednesday. Royal Bank of Canada restated an “outperform” rating and issued a $128.00 target price on shares of Abbott Laboratories in a research note on Wednesday, February 14th. Raymond James boosted their target price on Abbott Laboratories from $124.00 to $127.00 and gave the company an “outperform” rating in a research note on Thursday, January 25th. TheStreet upgraded Abbott Laboratories from a “c+” rating to a “b-” rating in a research note on Thursday, December 21st. Finally, Barclays boosted their target price on Abbott Laboratories from $133.00 to $141.00 and gave the company an “overweight” rating in a research note on Friday, January 26th. Three investment analysts have rated the stock with a hold rating and ten have issued a buy rating to the company. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus target price of $121.92.

Check Out Our Latest Analysis on Abbott Laboratories

About Abbott Laboratories

(Free Report)

Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon.

Further Reading

Institutional Ownership by Quarter for Abbott Laboratories (NYSE:ABT)

Receive News & Ratings for Abbott Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Abbott Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.